Jason Segal

The market makes noise. I tell the story. ASX life sciences companies explained.

The Pulse Check

Can "soon" move the market? Deals Whispered, not Signed

May 1, 2026

•

5 min read

Can "soon" move the market? Deals Whispered, not Signed

Jason Segal

The Pulse Check

Sailing the 4Cs: Highlights from Reporting Season

Apr 30, 2026

•

3 min read

Sailing the 4Cs: Highlights from Reporting Season

Jason Segal

Dimerix (ASX: DXB)

Apr 29, 2026

•

13 min read

'Timing' or 'Time in' the Market? The Dimerix (ASX: DXB) Story

Jason Segal

The Pulse Check

Apr 28, 2026

•

2 min read

Compare the Care

Jason Segal

The Pulse Check

Apr 27, 2026

•

7 min read

Life in the FDA Fast Lane

Jason Segal

The Pulse Check

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Apr 24, 2026

•

7 min read

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Jason Segal

The Pulse Check

Blue Chipped: What happened to Cochlear (ASX: COH)?

Apr 23, 2026

•

4 min read

Blue Chipped: What happened to Cochlear (ASX: COH)?

Jason Segal

The Pulse Check

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

Apr 22, 2026

•

4 min read

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

Jason Segal

Emyria (ASX: EMD)

Apr 21, 2026

•

7 min read

The Economics of Psychedelic Therapy

Jason Segal

The Pulse Check

Trump Greenlights Psychedelics in the US for PTSD

Apr 20, 2026

•

2 min read

Trump Greenlights Psychedelics in the US for PTSD

Jason Segal

Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

My Second Armchair Pick: Emyria (ASX: EMD)

Jason Segal

Telix (ASX: TLX)

Apr 17, 2026

•

9 min read

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Jason Segal

The Pulse Check

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Riding the Peptidal Wave: Biotech Bounce Back

Jason Segal

The Pulse Check

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Jason Segal

The Pulse Check

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

When Shares Become the Vote: The 249D-ilemma

Jason Segal

Telix (ASX: TLX)

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

Telix lights up the deal docket for the ASX biotech sector

Jason Segal

The Pulse Check

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

While everyone is selling. Big Pharma is buying.

Jason Segal

The Pulse Check

Apr 9, 2026

•

6 min read

Market’s Rocking: A Green Day

Jason Segal

The Pulse Check

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Apr 8, 2026

•

15 min read

Second Mover Advantage: The Neuroscientific Biopharmaceutical (ASX: NSB) Story

Jason Segal

The Pulse Check

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Apr 7, 2026

•

21 min read

A 20-Year Rollercoaster: The Mesoblast (ASX: MSB) Story

Jason Segal

The Pulse Check

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Mar 31, 2026

•

18 min read

How to win the cannabis game: The Bioxyne (ASX: BXN) Story

Jason Segal

The Pulse Check

Mar 30, 2026

•

9 min read

Why Peptides Are Suddenly Everywhere

Jason Segal

Lumos Diagnostics (ASX: LDX)

Crowned then Clipped: When the Raise Gets There Before the Rally

Mar 27, 2026

•

6 min read

Crowned then Clipped: When the Raise Gets There Before the Rally

Jason Segal

Lumos Diagnostics (ASX: LDX)

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Mar 26, 2026

•

9 min read

Trading Halt, Massive Stakes: Lumos Awaits Its US$300M Verdict

Jason Segal

The Pulse Check

Mar 25, 2026

•

5 min read

Why Iran Matters for Biotech Investors

Jason Segal